CytRx Corporation is a biopharmaceutical company that focuses on research and development in the field of oncology. Their drug development pipeline includes INNO-206, which is currently in Phase Ib clinical trial and completing Phase Ib/II clinical trial for treatment of soft tissue sarcomas. They also have tamibarotene, which is currently in Phase IIb clinical trial for non-small-cell lung cancer and is undergoing clinical trial for acute promyelocytic leukemia.